Parameters of avoidable mortality from respiratory disease in Aktobe region in 2019 – 2023

Aim. To study the avoidable mortality from respiratory disease in Aktobe region in 2019 – 2023.

Materials and methods. To calculate avoidable mortality we used the methodology suggested by OECD and the Eurostat working group. The data collected from the National Research Center for Health Development in the Aktobe region. The data included number of deaths using International Classification of Diseases 10, also gender, and area as urban and rural. The preventable and treatable mortality, as well as absolute and relative changes and the average annual percentage change were included in analysis.

Results and discussion. Between 2019 and 2023, avoidable mortality from respiratory diseases showed a decline, with a notable decrease in urban areas and a slight increase in rural areas. Preventable mortality was higher in males than females, with chronic lower respiratory diseases being the leading cause, and rural areas experiencing significantly higher rates than urban areas. The trends in treatable mortality showed a consistent decline, particularly in urban areas, with rural females seeing the largest decrease. Preventable mortality from COVID-19 was higher in males overall, however in rural areas, females had higher rates.

Conclusion. The avoidable and preventable mortality from respiratory diseases declined overall from 2019 to 2023, though with significant regional and gender disparities. Urban areas had more improvements, while rural areas experienced slower progress and higher mortality rates, particularly among males. Continued targeted interventions, especially in rural areas, are necessary to reduce these disparities and improve health outcomes.

1. Goals (SDGs), and their implementation: A national global framework for health, development and equity needs a systems approach at every level. Br. Med. Bull. 2017; 124 (1): 81-90. https://doi.org/10.1093/bmb/ldx031

2. López J.L., Espinilla M., Verdejo Á. Evaluation of the Impact of the Sustainable Development Goals on an Activity Recognition Platform for Healthcare Systems. Sensors (Basel). 2023; 23 (7): 3563. https://doi.org/10.3390/s23073563

3. Ranabhat C.L., Acharya S.P., Adhikari C., Kim C.B. Universal health coverage evolution, ongoing trend, and future challenge: A conceptual and historical policy review. Front Public Health. 2023; 11: 1041459. https://doi.org/10.3389/fpubh.2023.1041459

4. Kraef C., Kallestrup P. After the Astana declaration: is comprehensive primary health care set for success this time? BMJ Glob. Health. 2019; 4 (6): e001871. https://doi.org/10.1136/bmjgh-2019-001871

5. Rutstein D.D., Berenberg W., Chalmers T.C., Child C.G., Fishman A.P., Perrin E.B. Measuring the quality of medical care. A clinical method. N. Engl. J. Med. 1976; 294 (11): 582-588. https://doi.org/10.1056/nejm197603112941104

6. Nolte E., McKee M. Does Health Care Save Lives? Avoidable Mortality Revisited. London: Nuffield Trust; 2004: 138.

7. Nolte E., McKee M. Variations in treatable mortality-trends in 16 high-income nations. Health Policy. 2011; 103 (1): 47-52. https://doi.org/10.1016/j.healthpol.2011.08.002

8. Canadian Institute for Health Information (CIHI). Health Indicators 2012. Ottawa, Ontario: CIHI; 2012: 128.

9. Australian Institute of Health and Welfare. https://www.aihw.gov.au/reports/life-expectancydeath/deaths-in-australia/contents/age-at-death

10. OECD. Avoidable mortality (preventable and treatable). In: Health at a Glance 2019: OECD Indicators. Paris: OECD Publishing; 2019: 243.

11. Hrzic R., Vogt T. The contribution of avoidable mortality to life expectancy differences and lifespan disparities in the European Union: a population-based study. Lancet Reg. Health Eur. 2024; 46: 101042. https://doi.org/10.1016/j.lanepe.2024.101042

12. Bahk J., Jung-Choi K. The Contribution of Avoidable Mortality to the Life Expectancy Gains in Korea between 1998 and 2017. Int. J. Environ. Res. Public Health. 2020; 17 (18): 6499. https://doi.org/10.3390/ijerph17186499

13. Papanicolas I., Riley K., Abiona O., Arvin M., Atsma F., Bernal-Delgado E., Bowden N., Blankart C.R., Deeny S., Estupiñán-Romero F., Gauld R., Haywood P., Janlov N., Knight H., Lorenzoni L., Marino A., Or Z., Penneau A., Schoenfeld A.J., Shatrov K., Stafford M., van de Galien O., van Gool K., Wodchis W., Jha A.K., Figueroa J.F. Differences in health outcomes for high-need highcost patients across high-income countries. Health Serv. Res. 2021; 56 (3): 1347-1357. https://doi.org/10.1111/1475-6773.13735

14. GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. E Clinical Medicine. 2023; 59: 101936. https://doi.org/10.1016/j.eclinm.2023.101936

15. Boers E., Barrett M., Su J.G. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. JAMA Netw. Open. 2023; 6 (12): e2346598. https://doi.org/10.1001/jamanetworkopen.2023.46598

16. Syamlal G., Kurth L.M., Dodd K.E., Blackley D.J., Hall N.B., Mazurek J.M. Chronic Obstructive Pulmonary Disease Mortality by Industry and Occupation – United States, 2020. MMWR Morb. Mortal. Wkly Rep. 2022; 71 (49): 1550-1554. https:// doi.org/10.15585/mmwr.mm7149a3

17. Kim S.H., Park J.E., Yang B., Kim S.Y., Kim Y.Y., Park J.H. National trend in the prevalence and mortality of COPD in South Korea from 2008 to 2017. BMJ Open Respir. Res. 2024; 11 (1): e0023 91. https://doi.org/10.1136/bmjresp-2024-002391

18. Marshall D.C., Al Omari O., Goodall R., Shalhoub J., Adcock I.M., Chung K.F., Salciccioli J.D. Trends in prevalence, mortality, and disabilityadjusted life-years relating to chronic obstructive pulmonary disease in Europe: an observational study of the global burden of disease database, 2001-2019. BMC Pulm. Med. 2022; 22 (1): 289. https://doi.org/10.1186/s12890-022-02074-z

19. Order of Target Groups of Persons Subject to Screening Studies. As Well As the Rules. Scope and Frequency of These Studies Acting Order Minister of Health of the Republic of Kazakhstan Dated October 30. 2020 No. ҚР ДСМ-174/2020. Registered with the Ministry of Justice of the Republic of Kazakhstan on November 2. 2020 No. 21572. (Kazakh or Russian). https://adilet.zan.kz/rus/docs/V2000021572

20. Yeraliyeva L., Issayeva A. Changes in death rates from lower respiratory infections between 1991 and 2019 in the Republic of Kazakhstan. Georgian Med. News. 2023; 335: 95-98.

21. Avoidable mortality: OECD/Eurostat lists of preventable and treatable causes of death (January 2022 version); 2022. https://www.oecd.org/health/health-systems/Avoidable-mortality-2019-Joint-OECD-Eurostat-List-preventable-treatablecauses-of-death.pdf

22. OECD Health Statistics Definitions, sources and methods; 2022. https://stats.oecd.org/index.aspx?queryid=96018

23. Centers for Disease Control and Prevention (CDC). Vital signs: avoidable deaths from heart disease, stroke, and hypertensive disease – United States, 2001 – 2010. MMWR Morb. Mortal Wkly Rep. 2013; 62 (35): 721-727.

24. Kosherbayeva L., Akhtayeva N., Tolganbayeva K., Samambayeva A. Trends in Avoidable Mortality in Kazakhstan From 2015 to 2021. Int. J. Health Policy Manag. 2024; 13: 7919. https://doi.org/10.34172/ijhpm.2024.7919

25. Kruk M.E., Gage A.D., Joseph N.T., Danaei G., García-Saisó S., Salomon J.A. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of treatable deaths in 137 countries. Lancet. 2018; 392 (10160): 2203-2212. https://doi.org/10.1016/S0140-6736(18)31668-4

26. Kupek E. Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023. Vaccine. 2024; 42 (15): 3437-3444. https://doi.org/10.1016

27. Hacker K.A., Briss P.A., Richardson L., Wright J., Petersen R. COVID-19 and Chronic Disease: The Impact Now and in the Future. Prev. Chronic Dis. 2021; 18: E62. https://doi.org/10.5888/pcd18.210086

28. Balasuriya L., Briss P.A., Twentyman E., Wiltz J.L., Richardson L.C., Bigman E.T., Wright J.S., Petersen R., Hannan C.J., Thomas C.W., Barfield W.D., Kittner D.L., Hacker K.A. Impacts of the COVID-19 Pandemic on Nationwide Chronic Disease Prevention and Health Promotion Activities. Am. J. Prev. Med. 2023; 64 (3): 452-458. https://doi.org/10.1016/j.amepre.2022.09.012

29. Roche B., Garchitorena A., Guégan J.F., Arnal A., Roiz D., Morand S., Zambrana-Torrelio C., Suzán G., Daszak P. Was the COVID-19 pandemic avoidable? A call for a «solution-oriented» approach in pathogen evolutionary ecology to prevent future outbreaks. Ecol. Lett. 2020; 23 (11): 1557-1560. https://doi.org/10.1111/ele.13586

30. Pérez G., Rodríguez-Sanz M., Cirera E., Pérez K., Puigpinós R., Borrell C. Commentary: approaches, strengths, and limitations of avoidable mortality. J. Public. Health Policy. 2014; 35 (2): 171- 184. https://doi.org/10.1057/jphp.2014.8

31. Ammi M., Arpin E., Antoine Dedewanou F., Allin S. Do expenditures on public health reduce preventable mortality in the long run? Evidence from the Canadian provinces. Social Science & Medicine. 2024; 345: 116696. https://doi.org/10.1016/j.socscimed.2024.116696

32. Kiadaliri A. Avoidable deaths in Sweden, 1997-2018: temporal trend and the contribution to the gender gap in life expectancy. BMC Public Health. 2021; 21 (1): 519. https://doi.org/10.1186/s12889-021-10567-5

33. Nguyen N.T., Chinn J., De Ferrante M., Kirby K.A., Hohmann S.F., Amin A. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. PLoS One. 2021; 16 (7): e0254066. https://doi.org/10.1371/journal.pone.0254066

34. Moldayazova L., Zhapalakov B., Shagatayeva B., Kuatbaeva A., Baspakova A. The influence of environmental factors on the health of the population of the Aktobe region. Integr. Environ. Assess. Manag. 2024; 20 (4): 1156-1165. https://doi.org/10.1002/ieam.4862

35. Iskakov A.Zh. Characteristics of chemical pollution of snow cover in Aktobe areas. Gig. Sanit. 2010; 2:17-8.

36. Bekmukhambetov Y., Mamyrbayev A., Jarkenov T., Abilov T., Sultanova G., Isaeva G., Zhailybayev M., Uraz R. Interdisciplinary Approaches to Assessing the Health of People Living in Environmentally Adverse Conditions. Iran J. Public Health. 2019; 48 (9): 1627-1635.